Dual-Incretin and Muscle-Preservation Therapeutic Strategies for Metabolic Disease Management

Abstract

Metabolic diseases, particularly type 2 diabetes mellitus (T2DM) and obesity, continue to present significant global health challenges due to their high prevalence, associated morbidity, and economic burden. Recent advancements in dual-incretin therapies—agents targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors—offer promising glycemic and weight management benefits. Parallelly, muscle-preservation strategies have gained clinical relevance, given the risks of sarcopenia and functional decline associated with metabolic diseases and their treatments. This review synthesizes the latest evidence on dual-incretin approaches and muscle-preservation tactics, focusing on mechanistic insights, clinical outcomes, and guideline-aligned recommendations for comprehensive metabolic disease management.

Introduction

Metabolic diseases, including T2DM and obesity, represent a complex interplay of genetic, environmental, and lifestyle factors. Traditional management strategies have focused on glycemic control, weight reduction, and cardiovascular risk mitigation. However, the evolving understanding of metabolic pathophysiology has paved the way for innovative therapies targeting multiple hormonal pathways and preserving lean body mass. Dual-incretin therapies, such as tirzepatide, harness the synergistic effects of GLP-1 and GIP receptor activation to promote glucose homeostasis and weight loss. Simultaneously, the preservation of skeletal muscle mass is emerging as a critical therapeutic goal to prevent sarcopenia, frailty, and reduced quality of life in patients with metabolic disease. This article provides an in-depth analysis of these contemporary strategies, integrating mechanistic, clinical, and practical perspectives for healthcare professionals.

Epidemiology / Disease Burden

The global prevalence of T2DM and obesity has risen dramatically over recent decades, with the International Diabetes Federation estimating over 537 million adults living with diabetes in 2021. Obesity, affecting more than 650 million adults worldwide, is a leading risk factor for T2DM and cardiovascular disease. Metabolic diseases account for a substantial proportion of healthcare expenditures and are associated with increased morbidity, mortality, and reduced life expectancy. Importantly, the burden of sarcopenia is often underappreciated in this population, with studies demonstrating a higher prevalence of muscle loss and functional impairment among individuals with T2DM and obesity, exacerbating the risk for disability and hospitalization.

Pathophysiology

Metabolic diseases are characterized by insulin resistance, impaired glucose metabolism, and chronic low-grade inflammation. GLP-1 and GIP are incretin hormones secreted by the gut in response to nutrient ingestion, augmenting insulin secretion in a glucose-dependent manner. In T2DM, there is a relative deficiency and diminished efficacy of endogenous incretins, contributing to hyperglycemia. Muscle loss in metabolic disease arises from anabolic resistance, increased protein catabolism, and inflammatory cytokine activity. Adipose tissue dysfunction, mitochondrial impairment, and hormonal imbalances further disrupt glucose uptake and muscle protein synthesis, perpetuating the cycle of metabolic dysfunction and sarcopenia.

Risk Factors

Key risk factors for metabolic diseases include genetic predisposition, sedentary lifestyle, poor dietary habits, aging, and comorbid conditions such as hypertension and dyslipidemia. The risk of sarcopenia is heightened by chronic hyperglycemia, systemic inflammation, physical inactivity, and inadequate protein intake. Pharmacotherapies inducing rapid weight loss may inadvertently accelerate muscle loss, underscoring the need for integrated strategies that address both metabolic control and muscle preservation.

Clinical Features

Patients with T2DM and obesity present with variable clinical manifestations, ranging from asymptomatic hyperglycemia to overt metabolic syndrome, microvascular complications, and cardiovascular events. Sarcopenia may manifest as reduced muscle strength, physical performance, and increased risk of falls or frailty. Early identification of muscle loss is essential, as it often coexists with obesity (sarcopenic obesity), complicating the clinical picture and therapeutic approach.

Diagnosis

The diagnosis of metabolic diseases hinges on clinical assessment, laboratory evaluation of fasting plasma glucose, HbA1c, lipid profiles, and anthropometric measurements (BMI, waist circumference). Sarcopenia is diagnosed based on criteria that include reduced muscle mass (assessed by DXA or BIA), decreased muscle strength (handgrip dynamometry), and impaired physical performance (gait speed, chair stand tests). Comprehensive evaluation enables tailored interventions addressing both metabolic control and functional status.

Treatment & Management

Current management of metabolic diseases involves lifestyle modification, pharmacotherapy, and risk factor optimization. Lifestyle interventions promote healthy eating, increased physical activity, and weight reduction. Pharmacologic agents include metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin, with emerging recognition of the superior efficacy of dual-incretin therapies. Muscle-preservation strategies incorporate resistance training, adequate protein intake (1.0–1.2 g/kg/day), and, in select cases, anabolic agents or myostatin inhibitors. Multidisciplinary care including nutritionists, physiotherapists, and endocrinologists is pivotal for optimizing patient outcomes.

Recent Advances / Emerging Therapies

Dual-incretin receptor agonists, exemplified by tirzepatide, have demonstrated robust HbA1c reductions and superior weight loss compared to GLP-1 agonists alone, as evidenced in the SURPASS clinical trials. Mechanistically, co-activation of GIP and GLP-1 receptors enhances insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite. These agents also exhibit cardiovascular and renal benefits, expanding their therapeutic appeal. In parallel, research into muscle-preserving pharmacotherapies—such as selective androgen receptor modulators (SARMs), anti-myostatin antibodies, and novel nutritional interventions—offers hope for mitigating sarcopenia in metabolic disease populations. Integrating dual-incretin therapy with structured exercise and protein supplementation may yield synergistic benefits on metabolic and musculoskeletal health.

Guideline Recommendations

Recent guidelines from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) endorse the use of GLP-1 receptor agonists and, where available, dual-incretin agents as second-line options for patients with T2DM and obesity, particularly those with cardiovascular risk. Nutritional and exercise interventions remain foundational, with recommendations emphasizing resistance training for muscle preservation. Screening for sarcopenia is advised in high-risk populations, and therapy should be individualized based on comorbidities, patient preferences, and functional status.

Conclusion

Innovative dual-incretin therapies and muscle-preservation strategies represent significant advances in the management of metabolic diseases. By targeting multiple pathogenic pathways and prioritizing functional outcomes, these approaches promise to improve glycemic control, reduce obesity-related complications, and maintain musculoskeletal integrity. Continued research, interdisciplinary collaboration, and guideline-driven care are essential to translating these advances into optimal patient outcomes in clinical practice.